Summary

Promising utility of using serial ctDNA in metastatic colorectal cancer to both refine patient selection, reduce toxicity due to chemotherapy, and to evaluate emerging resistance mechanisms may lead the way to novel therapeutic strategies. However, important questions remain in validating its use as a predictive biomarker of treatment response.

See related article by Vidal et al., p. 379

©2022 American Association for Cancer Research
2022
American Association for Cancer Research
You do not currently have access to this content.